Cubist Pharmaceuticals has commenced patient enrolment in its Phase III CB-5945 ascent study for the treatment of opioid-induced constipation (OIC).

The multicentre, long-term safety study is one of four registrational studies conducted in patients with chronic non-cancer pain.

The randomised (1:1), double-blind, placebo-controlled study is designed to evaluate CB-5945 (0.25mg twice a day) and will enrol 1,400 eligible patients in the US and Canada.

Cubist chief scientific officer Dr Steve Gilman said that for millions of people with chronic non-cancer pain, opioid-induced constipation is a debilitating side effect.

"For millions of people with chronic non-cancer pain, opioid-induced constipation is a debilitating side effect."

"We are excited to begin the robust Phase III development program for CB-5945 and hope one day to make this important therapy available for patients," Gilman said.

The safety of CB-5945 (0.25mg twice a day) compared with placebo over a one-year treatment period is the primary objective of the study, while the effects of the candidate on quality of life is a secondary objective.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

A total of nearly 3,200 patients are expected to be enrolled in the Phase III programme.

CB-5945 is a potent, peripherally acting mu opioid receptor antagonist designed to block the adverse effects of opioid analgesics on the gastrointestinal tract without affecting the centrally mediated pain relief.